Free tool
FAERS Monitor: Lamictal Odt
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022251 or its brand name (Lamictal Odt, Lamotrigine). Reports on generic versions are filed under their own applications.
Reports
131,818
Serious
95,257
72% of reports
Hospitalization
40,669
Death reported
11,489
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective10,339
- rash8,692
- seizure6,714
- nausea6,457
- off label use6,296
- fatigue6,266
- dizziness6,077
- headache5,815
- depression5,273
- vomiting4,850
- somnolence4,542
- pyrexia4,522
- drug interaction4,517
- anxiety4,499
- toxicity to various agents4,368
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2,016 |
| 2005 | 3,052 |
| 2006 | 3,557 |
| 2007 | 3,880 |
| 2008 | 2,377 |
| 2009 | 4,889 |
| 2010 | 3,761 |
| 2011 | 4,928 |
| 2012 | 5,259 |
| 2013 | 4,636 |
| 2014 | 5,129 |
| 2015 | 7,174 |
| 2016 | 7,478 |
| 2017 | 7,208 |
| 2018 | 8,199 |
| 2019 | 8,580 |
| 2020 | 7,704 |
| 2021 | 7,243 |
| 2022 | 6,632 |
| 2023 | 6,990 |
| 2024 | 7,677 |
| 2025 | 7,874 |
| 2026 | 5,574 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,922,341 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| seizureSignal | 6,714 | 9.8 | 9.6 | 50,146 |
| drug interactionSignal | 4,517 | 4.6 | 4.5 | 12,652 |
| toxicity to various agentsSignal | 4,368 | 4.2 | 4.1 | 10,520 |
| depressionSignal | 5,273 | 3.8 | 3.7 | 10,555 |
| somnolenceSignal | 4,542 | 3.7 | 3.6 | 8,660 |
| rashSignal | 8,692 | 3.2 | 3.2 | 13,360 |
| anxietySignal | 4,499 | 2.5 | 2.5 | 4,216 |
| pyrexiaSignal | 4,522 | 2.1 | 2.0 | 2,612 |
| dizziness | 6,077 | 2.0 | 1.9 | 2,871 |
| vomiting | 4,850 | 1.7 | 1.6 | 1,265 |
| headache | 5,815 | 1.5 | 1.4 | 938 |
| nausea | 6,457 | 1.3 | 1.3 | 472 |
| fatigue | 6,266 | 1.3 | 1.3 | 411 |
| drug ineffective | 10,339 | 1.3 | 1.2 | 562 |
| off label use | 6,296 | 1.1 | 1.1 | 125 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.